All In Biotech

Drug Trial Radar · NCT00391872

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inhibition and Patient Outcomes]

Last checked: Nov 20, 2026Latest source record: Mar 13, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 18,624 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

18,624

Actual

Start

Oct 2006

Primary completion

Mar 2009

Study completion Mar 2009

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 25, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS.

Conditions

  • Acute Coronary Syndrome

Interventions

  • TicagrelorDrug

    Ticagrelor (AZD6140) 90 mg twice daily dose (BD)

  • ClopidogrelDrug

    Clopidogrel 75 mg once daily dose (ODD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and StrokeTime frame: Randomization up to 12 months
  2. Participants With Any Major Bleeding EventTime frame: First dosing up to 12 months

Locations

672 sites in 44 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Tucson, Arizona

  • Research Site

    Bakersfield, California

  • Research Site

    Beverly Hills, California

  • Research Site

    Burbank, California

  • Research Site

    Healdsburg, California

  • Research Site

    Los Angeles, California

  • Research Site

    Roseville, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    Torrance, California

  • Research Site

    Fort Collins, Colorado

  • Research Site

    Danbury, Connecticut

  • Research Site

    Hartford, Connecticut

  • Research Site

    Newark, Delaware

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Atlantis, Florida

  • Research Site

    Daytona Beach, Florida

  • Research Site

    Fort Lauderdale, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Jupiter, Florida

  • Research Site

    Melbourne, Florida

  • Research Site

    Miami Beach, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Ormond Beach, Florida

  • Research Site

    Pensacola, Florida

  • Research Site

    Sarasota, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Park Ridge, Illinois

  • Research Site

    Rock Island, Illinois

  • Research Site

    Rockford, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Muncie, Indiana

  • Research Site

    Valparaiso, Indiana

  • Research Site

    Iowa City, Iowa

Showing 40 of 672 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.